Verification of the test procedure for a Haemophilus type b conjugate vaccine by determination of capsular polysaccharide


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Many developed countries in the world have included vaccine against infection caused by Haemophilus influenzae type b in their national immunization programs. One of the main quality indicators of vaccine is its specific activity determined by the content of the capsular polysaccharide polyribosylribitol phosphate (PRP). Objective: to verify the spectrophotometric determination of phosphorus for the control of hemophilustype b capsular polysaccharide conjugate vaccine in accordance with the requirements of the 14th Edition of the State Pharmacopoeia of the Russian Federation (RF SP-14). Material and methods. The investigation object was a hemophilus type b conjugate vaccine, lyophilisate for solution for intramuscular injection. The procedure given in GPA 1.7.2.0017.15 «Spectrophotometric Determination of Phosphorus in Biological Agents» was verified in accordance with the requirements of the RF SP-14. Results. While verifying the procedure, the investigators estimated the following parameters: correctness, reproductibility, and intralaboratory precision. The results were found to be dissimilar. The optimal conditions for the procedure were selected for the subject and standard (calibration) samples; it was recommended to use a single control sample. Samples should be prepared under similar conditions. Conclusion. The procedure for spectrophotometric determination of phosphorus has been optimized, which makes it possible to obtain reliable results by the quantitative indicator capsular polysaccharide for the hemophilic type b conjugate vaccine, lyophilisate for solution for intramuscular injection.

Full Text

Restricted Access

About the authors

Anastasia Aleksandrovna Ivanova

Saint Petersburg Research Institute of Vaccines and Serums and Enterprise for the Production of Bacterial Preparations, Federal Biomedical Agency of Russia

Email: an.a.ivanova@spbniivs.ru

Anastasia Dmitrievna Konon

Saint Petersburg Research Institute of Vaccines and Serums and Enterprise for the Production of Bacterial Preparations, Federal Biomedical Agency of Russia

Email: a.d.konon@spbniivs.ru

Elena Leonidovna Salimova

Saint Petersburg Research Institute of Vaccines and Serums and Enterprise for the Production of Bacterial Preparations, Federal Biomedical Agency of Russia

Email: e.l.salimova@spbniivs.ru

Viktor Pavlovich Trukhin

Saint Petersburg Research Institute of Vaccines and Serums and Enterprise for the Production of Bacterial Preparations, Federal Biomedical Agency of Russia

Email: v.p.truhin@spbniivs.ru

References

  1. Документ по позиции ВОЗ. Вакцинация против гемофильной инфекции типа b (Hib). Еженедельный эпидемиологический бюллетень, 2013; Т. 88:413-28.[Электронный ресурс]. Режим доступа: https://www.who.int/immunization/documents/Hib_Refs_ Rus.pdf?ua=1 (дата обращения: 14.01.2019)
  2. Chongmelaxme B., Hammanee M., Phooaphirak W. еt al. Economic evaluations of Haemophilus influenza type b (Hib) vaccine: asystematic review. Journal of Medical Economics, 2017; 20(10): 1094-1106. doi: 10.1080/13696998.2017.1359181
  3. Государственная фармакопея Российской Федерации XIV изд. [Электронныйресурс]. Режим доступа: http://femb.ru/feml [The State Pharmacopoeia of the Russian Federation, XIV-th ed. [Electronic resource]. Access mode: http://femb.ru/feml (in Russian)].
  4. Tsai C.M. Quantitation of Polysaccharide in Hib Conjugate Vaccines. [Electronicresource]. Accessmode: http://grantome.com/ grant/NIH/Z01-BJ002009-07
  5. Tsai C.M., Gu X.X., Byrd R.A. Quantification of polysaccharide in Haemophilus influenza type b conjugate and polysaccharide vaccines by high-performance anion-exchange chromatography with pulsed amperometric detection. Vaccine, 1994; 12: 700-13.
  6. He P.F., Li Y.N., Tang J., Ye Q. Determination of polysaccharide content in Haemophilus influenzae type b conjugate vaccines by high performance anion exchange chromatography-pulsed amperometric detector. Chinese Journal of Biologicals, 2013; 26: 1002-5. doi: 10.1016/0264-410X(94)90219-4
  7. Yoo T.H., Kim H.S., Park S.S., Bang E.Y. et al. Measurement of Free Polysaccharide in Tetanus Toxoid-Conjugate Vaccine Using Antibody/Ammonium Sulfate Precipitation.Journal of Microbiology and Biotechnology, 2003; 13: 469-72.
  8. Hamidi A., Kreeftenberg H.Use of immune assays during the development of Haemophilus influenzae type b vaccine fortechnology transfer to emerging vaccine manufacturer. Human Vaccines & Immunotherapeutics, 2014; 10: 2697-703.doi: 10.4161/hv.29300
  9. Белякова О.В. Разработка и валидация методики определения полирибозилрибитолафосфата в конъюгированных вакцинах для профилактики инфекции, вызываемой Haemophilus influenza типа b. Биофармацевтический журнал, 2015; 2: 21-4. [Belyakova O.V. Development and validation of the method for determining polyribosylribitol phosphate in conjugated vaccines for the prevention of infection caused by Haemophilus influenzae type b. Biofarmatsevticheskii zhurnal, 2015; 2: 21-4. (in Russian)].
  10. Европейская фармакопея 8.0, 2015; 1: 212.(издание на русском языке).

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies